Genzyme Corporation Announces European Medicines Evaluation Agency Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis

Published: Feb 23, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the European Medicines Agency (EMA) has accepted the filing of the marketing authorization application (MAA) for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis (MS). Acceptance of the MAA starts the EMA’s review process.

Back to news